Erratum to Using systems approaches to address challenges for clinical implementation of pharmacogenomics[WIREs Syst Biol Med (2014), 6:125-135. doi: 10.1002/wsbm.1255];Using systems approaches to address challenges for clinical implementation of pharmacogenomics

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 6, Issue 2, 2014, Pages 125-135

  Karnes, Jason H ^a   Van Driest, Sara ^b   Bowton, Erica A ^a   Weeke, Peter E ^a   Mosley, Jonathan D ^a   Peterson, Josh F ^a,c   Denny, Joshua C ^a,c   Roden, Dan M ^a,d  

^a VANDERBILT UNIVERSITY   (United States)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DECISION SUPPORT SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART REPOLARIZATION; HUMAN; LAW; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; POINT OF CARE TESTING; POTASSIUM CURRENT; PUBLIC HEALTH; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL NETWORK;

GENOTYPE; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 84894043532     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.1298     Document Type: Erratum

References (54)

1. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998, 8:283-289.
2. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 2001, 285:540-544.
3. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440:1073-1077.
4. Ahn K, Luo J, Berg A, Keefe D, Wu R. Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles. Trends Pharmacol Sci 2010, 31:306-311.
5. Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 2013, 14:723-726.
6. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012, 92:87-95.
7. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011, 68:143-150.
8. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012, 92:446-449.
9. Shuldiner AR, Relling MV, Peterson JF, Hicks K, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE. The pharmacogenomics research network translational pharmacogenetics program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013, 94:207-210.
10. Koster ES, Rodin AS, Raaijmakers JA, Maitland-van der Zee AH. Systems biology in pharmacogenomic research: the way to personalized prescribing? Pharmacogenomics 2009, 10:971-981.
11. Rodin AS, Gogoshin G, Boerwinkle E. Systems biology data analysis methodology in pharmacogenomics. Pharmacogenomics 2011, 12:1349-1360.
12. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013, 502:377-380.
13. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, Lutjohann D, Smet J, Van Coster R, Seppanen-Laakso T, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1:e97.
14. Tamada Y, Araki H, Imoto S, Nagasaki M, Doi A, Nakanishi Y, Tomiyasu Y, Yasuda K, Dunmore B, Sanders D, et al. Unraveling dynamic activities of autocrine pathways that control drug-response transcriptome networks. Pac Symp Biocomput 2009:251-263.
15. Araki H, Tamada Y, Imoto S, Dunmore B, Sanders D, Humphrey S, Nagasaki M, Doi A, Nakanishi Y, Yasuda K, et al. Analysis of PPARα-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells. Angiogenesis 2009, 12:221-229.
16. Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A, Sanna S, Arking DE, Amsterdam AH, Sabeh KM, Mably JD, et al. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 2009, 120:553-559.
17. Jonsson MKB, Vos MA, Mirams GR, Duker G, Sartipy P, de Boer TP, van Veen TAB. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol 2012, 52:998-1008.
18. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Wang PJ, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013, 127:1677-1691.
19. Dahlin A, Tantisira KG. Integrative systems biology approaches in asthma pharmacogenomics. Pharmacogenomics 2012, 13:1387-1404.
20. Himes BE, Wu AC, Duan QL, Klanderman B, Litonjua AA, Tantisira K, Ramoni MF, Weiss ST. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics 2009, 10:1393-1412.
21. Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M, Helgadottir H, Gudmundsdottir AS, Andrason H, Adalsteinsdottir AE, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A 2005, 102:14789-14794.
22. Novershtern N, Itzhaki Z, Manor O, Friedman N, Kaminski N. A functional and regulatory map of asthma. Am J Respir Cell Mol Biol 2008, 38:324-336.
23. Lara J, Xia G, Purdy M, Khudyakov Y. Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol 2011, 85:3649-3663.
24. Deforche K, Camacho RJ, Grossman Z, Soares MA, Van Laethem K, Katzenstein DA, Harrigan PR, Kantor R, Shafer R, Vandamme AM. Bayesian network analyses of resistance pathways against efavirenz and nevirapine. AIDS 2008, 22:2107-2115.
25. Kohane IS. Using electronic health records to drive discovery in disease genomics. Nat Rev Genet 2011, 12:417-428.
26. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010, 11:241-246.
27. Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS. A population approach to precision medicine. Am J Prev Med 2012, 42:639-645.
28. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
29. Galea S, Riddle M, Kaplan GA. Causal thinking and complex system approaches in epidemiology. Int J Epidemiol 2010, 39:97-106.
30. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010, 12:686-693.
31. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009, 24:656-664.
32. Khoury MJ, Gwinn M, Bowen MS, Dotson WD. Beyond base pairs to bedside: a population perspective on how genomics can improve health. Am J Public Health 2012, 102:34-37.
33. Chambers D, Wilson P, Thompson C, Harden M. Social network analysis in healthcare settings: a systematic scoping review. PLoS One 2012, 7:e41911.
34. Anderson JG. Evaluation in health informatics: social network analysis. Comput Biol Med 2002, 32:179-193.
35. Samarth CN, Gloor PA. Process efficiency. Redesigning social networks to improve surgery patient flow. J Healthc Inf Manage 2009, 23:20-26.
36. Benham-Hutchins MM, Effken JA. Multi-professional patterns and methods of communication during patient handoffs. Int J Med Inform 2010, 79:252-267.
37. Sykes TA, Venkatesh V, Rai A. Explaining physicians' use of EMR systems and performance in the shakedown phase. J Am Med Inform Assoc 2011, 18:125-130.
38. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:651-681.
39. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, Churchill D, Cromarty B, Das S, Fisher M, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
40. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012, 91:734-738.
41. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:625-629.
42. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011, 90:328-332.
43. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE, Fesmire FM, Hochman JS, Levin TN, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the american college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013, 127:e663-828.
44. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2011, 2012:453-495.
45. Mrazek DA, Lerman C. Facilitating clinical implementation of pharmacogenomics. JAMA 2011, 306:304-305.
46. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
47. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
48. Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004, 151:1123-1132.
49. Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, Beitelshees AL, Dane A, Reijmers T, Hankemeier T, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2013, 94:525-532.
50. Scott SA. Clinical pharmacogenomics: opportunities and challenges at point of care. Clin Pharmacol Ther 2013, 93:33-35.
51. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
52. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012, 91:450-458.
53. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet 2012, 82:388-394.
54. Stead WW, Searle JR, Fessler HE, Smith JW, Shortliffe EH. Biomedical informatics: changing what physicians need to know and how they learn. Acad Med 2011, 86:429-434.